GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas

Human Pathology

Volumn 47, Issue 1, 2016, Pages 26-31

  Davis, Drew G ^a   Siddiqui, Momin T ^a   Oprea Ilies, Gabriela ^a   Stevens, Keith ^a   Osunkoya, Adeboye O ^a   Cohen, Cynthia ^a   Li, Xiaoxian ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

Breast; Carcinoma; FOXA1; GATA 3; IHC; Mesothelioma; Prostatic; TMA; Unknown primary tumor; Urothelial

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; TRANSCRIPTION FACTOR GATA 3; FOXA1 PROTEIN, HUMAN; GATA3 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BREAST CARCINOMA; COLON CARCINOMA; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVARY CARCINOMA; PANCREAS CARCINOMA; PROSTATE CARCINOMA; PROTEIN EXPRESSION; STOMACH CARCINOMA; TRANSITIONAL CELL CARCINOMA; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; CANCER OF UNKNOWN PRIMARY SITE; CARCINOMA; CHEMISTRY; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; EVALUATION STUDY; IMMUNOHISTOCHEMISTRY; PATHOLOGY; PREDICTIVE VALUE; SECONDARY; TISSUE MICROARRAY;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA; DIAGNOSIS, DIFFERENTIAL; FEMALE; GATA3 TRANSCRIPTION FACTOR; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASMS, UNKNOWN PRIMARY; PREDICTIVE VALUE OF TESTS; TISSUE ARRAY ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84951852663     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2015.09.015     Document Type: Article

References (25)

1. B.Z. Clark, S. Beriwal, D.J. Dabbs, and R. Bhargava Immunoreactivity in breast, bladder, gynecologic tract, and other cytokeratin 7-positive carcinomas Am J Clin Pathol 142 2014 64 71
2. H. Liu, J. Shi, J.W. Prichard, Y. Gong, and F. Lin Immunohistochemical expression in ER-negative breast carcinomas Am J Clin Pathol 141 2014 648 655
3. R.V. Hoch, D.A. Thompson, R.J. Baker, and R.J. Weigel GATA-3 is expressed in association with estrogen receptor in breast cancer Int J Cancer 84 1999 122 128
4. C.M. Perou, T. Sorlie, D. Botstein, and et al. Molecular portraits of human breast tumours Nature 406 2000 747 752
5. M.L. Asselin-Labat, K.D. Sutherland, J.E. Visvader, and et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation Nat Cell Biol 9 2007 201 208
6. H. Liu, J. Shi, M.L. Wilkerson, and F. Lin Immunohistochemical evaluation of GATA-3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas Am J Clin Pathol 138 2012 57 64
7. M. Miettinen, P.A. McCue, M. Sarlomo-Rikala, and et al. GATA-3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial neoplasms Am J Surg Pathol 38 2014 13 21
8. P. Carlsson, and M. Mahlapuu Forkhead transcription factors: key players in development and metabolism Dev Biol 250 2002 1 23
9. J.S. Carroll, and M. Brown Estrogen receptor target gene: an evolving concept Mol Endocrinol 20 2006 1707 1714
10. J.S. Carroll, X.S. Liu, A.S. Brodsky, and et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FOXA1 Cell 122 2005 33 43
11. J. Laganiere, G. Deblois, C. Lefebvre, A.R. Bataille, F. Robert, and V. Giguere Location analysis of estrogen receptor α target promoters reveals that FOXA1 defines a domain of the estrogen response PNAS 102 2005 11651 11656
12. M.A. Thorat, C. Marchio, A. Morimiya, and et al. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis J Clin Pathol 61 2008 327 332
13. F.O. Ademuyiwa, M.A. Thorat, R.K. Jain, H. Nakshatri, and S. Badve Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence score Mod Pathol 23 2010 270 275
14. K.H. Kaestner The FoxA factors in organogenesis and differentiation Curr Opin Genet Dev 20 2010 527 532
15. Y. Zhao, D.J. Tindall, and H. Huang Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer Int J Biol Sci 10 2014 614 619
16. M.L. Wilkerson, and E. Powell Tissue microarray F. Lin, J. Prichard, H. Liu, Handbook of practical immunohistochemistry: frequently asked questions 2011 Springer New York, NY 45 54
17. P. Mhawech-Fauceglia, B. Kay, C.J. Li, and Y.G. Lin Metastatic ovarian papillary serous carcinoma to the breast: diagnosis and pitfalls Gynecol Oncol Case Rep 4 2013 35 37
18. A. Cimino-Matthews, A.P. Subhawong, P.B. Illei, and et al. GATA-3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas Hum Pathol 44 2013 1341 1349
19. Y. Hisamatsu, E. Tokunaga, N. Yamashita, and et al. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer Breast Cancer 1-9 2014
20. N. Fatima, and A.O. Osunkoya GATA-3 expression in sarcomatoid urothelial carcinoma of the bladder Hum Pathol 45 2014 1625 1629
21. H.J. Jin, J.C. Zhao, L. Wu, and J. Yu Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program Nat Commun 5 2014 3972
22. Y. Imamura, S. Sakamoto, T. Endo, and et al. FOXA1 promotes tumor progression in prostate cancer via the insulin-like growth factor binding protein 3 pathway PLoS One 7 2012 e42456
23. A. Albergaria, J. Paredes, B. Sousa, and et al. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumors Breast Cancer Res 11 2009 R40
24. D.J. DeGraff, P.E. Clark, J.M. Cates, and et al. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation PLoS One 7 2012 e36669
25. N.G. Ordóñez, and A.A. Sahin Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study Hum Pathol 45 2014 1529 1540